A. Cervantes

Annals of Oncology · 2005–2022

A researcher in the Science corpus: 16 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom A. Cervantes trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. B. Nordlinger

Papers from A. Cervantes's perspective

Ordered by how strongly the researchers A. Cervantes trusts endorse each paper. Same corpus, a different order for every researcher.

1. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (The Lancet Oncology)
2. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (Journal of Clinical Oncology)
3. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (Journal of Clinical Oncology)
4. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR (Nature)
5. Actual 10-year survival after resection of colorectal liver metastases defines cure. (Journal of Clinical Oncology)
6. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival (Annals of Surgery)
7. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated,… (Journal of Clinical Oncology)
8. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
9. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. (The Lancet Oncology)
10. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (Journal of Clinical Oncology)

Their papers

• A phase 3 trial of bevacizumab in ovarian cancer. (2011) — 2,021 citations
• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. (2013) — 661 citations
• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2022) — 1,085 citations
• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2022) — 1,490 citations
• Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. (2020) — 1,246 citations
• Integration of oncology and palliative care: a Lancet Oncology Commission. (2018) — 643 citations
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) — 3,178 citations
• Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial (2015) — 794 citations
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) — 1,102 citations
• Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) — 882 citations
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012) — 1,471 citations
• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) — 917 citations
• Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) (2010) — 597 citations
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. (2010) — 976 citations
• OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. (2006) — 721 citations
• Capecitabine as adjuvant treatment for stage III colon cancer. (2005) — 1,201 citations